SEC Comment Letter 0000000000-25-000730 to Vivos Therapeutics, Inc. (VVOS)
Vivos Therapeutics, Inc.
Date: Jan. 23, 2025 · CIK: 0001716166 · Accession: 0000000000-25-000730
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-284399
Letter
January 23, 2025 R. Kirk Huntsman Chairman of the Board and Chief Executive Officer Vivos Therapeutics, Inc. 7921 Southpark Plaza, Suite 210 Littleton, Colorado 80120 Re:Vivos Therapeutics, Inc. Registration Statement on Form S-1 Filed January 22, 2025 File No. 333-284399 Dear R. Kirk Huntsman: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Conlon Danberg at 202-551-4466 with any questions. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services cc:Lawrence A. Rosenbloom, Esq.
Show Raw Text
January 23, 2025
R. Kirk Huntsman
Chairman of the Board and Chief Executive Officer
Vivos Therapeutics, Inc.
7921 Southpark Plaza, Suite 210
Littleton, Colorado 80120
Re:Vivos Therapeutics, Inc.
Registration Statement on Form S-1
Filed January 22, 2025
File No. 333-284399
Dear R. Kirk Huntsman:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Conlon Danberg at 202-551-4466 with any questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services
cc:Lawrence A. Rosenbloom, Esq.